RecruitingPhase 2NCT06572618

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

A Phase 2 Study of BTK Inhibitor Nemtabrutinib in Combination With Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Sponsor

City of Hope Medical Center

Enrollment

27 participants

Start Date

Jan 22, 2025

Study Type

INTERVENTIONAL

Conditions

Mantle Cell Lymphoma

Summary

This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib with rituximab may kill more cancer cells in patients with mantle cell lymphoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of two drugs — nemtabrutinib and rituximab — for people newly diagnosed with mantle cell lymphoma (a type of non-Hodgkin lymphoma) who have not yet received any systemic treatment. Nemtabrutinib is a newer type of BTK inhibitor (a targeted therapy that blocks cancer cell growth signals). **You may be eligible if...** - You are 18 or older - You have been diagnosed with mantle cell lymphoma confirmed by biopsy - You have not received any prior systemic cancer treatment for this condition - Your ECOG performance status is 2 or better - You have lab, imaging, or symptom evidence of lymphoma that requires treatment **You may NOT be eligible if...** - You have already received systemic treatment for mantle cell lymphoma - You have serious organ problems or infections - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.